Citadel Advisors
APLS

Citadel Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Citadel Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Sell
68,600
-55,400
-45% -$1.19M ﹤0.01% 5434
2025
Q4 		$3.11M Buy
124,000
+10,200
+9% +$239K ﹤0.01% 5086
2025
Q3 		$2.58M Buy
113,800
+39,500
+53% +$921K ﹤0.01% 5576
2025
Q2 		$1.29M Sell
74,300
-14,200
-16% -$263K ﹤0.01% 6559
2025
Q1 		$1.94M Sell
88,500
-45,400
-34% -$1.25M ﹤0.01% 5596
2024
Q4 		$4.27M Sell
133,900
-47,200
-26% -$1.42M ﹤0.01% 4216
2024
Q3 		$5.22M Buy
181,100
+8,800
+5% +$326K ﹤0.01% 3869
2024
Q2 		$6.61M Sell
172,300
-120,700
-41% -$5.47M ﹤0.01% 3333
2024
Q1 		$17.2M Sell
293,000
-115,400
-28% -$7.36M ﹤0.01% 2239
2023
Q4 		$24.4M Buy
408,400
+99,900
+32% +$5.07M ﹤0.01% 1815
2023
Q3 		$11.7M Buy
308,500
+92,900
+43% +$4.08M ﹤0.01% 2481
2023
Q2 		$19.6M Buy
215,600
+28,700
+15% +$2.48M ﹤0.01% 1903
2023
Q1 		$12.3M Sell
186,900
-8,800
-4% -$508K ﹤0.01% 2528
2022
Q4 		$10.1M Buy
195,700
+101,500
+108% +$5.38M ﹤0.01% 2828
2022
Q3 		$6.43M Buy
94,200
+30,300
+47% +$1.79M ﹤0.01% 3454
2022
Q2 		$2.89M Sell
63,900
-15,100
-19% -$688K ﹤0.01% 4823
2022
Q1 		$4.01M Buy
79,000
+17,500
+28% +$773K ﹤0.01% 4601
2021
Q4 		$2.91M Sell
61,500
-262,600
-81% -$10.3M ﹤0.01% 5400
2021
Q3 		$10.7M Buy
324,100
+235,200
+265% +$13.2M ﹤0.01% 2965
2021
Q2 		$5.62M Buy
88,900
+60,200
+210% +$3.11M ﹤0.01% 4183
2021
Q1 		$1.23M Buy
28,700
+16,900
+143% +$800K ﹤0.01% 7577
2020
Q4 		$675K Sell
11,800
-100
-0.8% -$4.23K ﹤0.01% 7566
2020
Q3 		$359K Sell
11,900
-41,300
-78% -$1.23M ﹤0.01% 7833
2020
Q2 		$1.74M Sell
53,200
-70,900
-57% -$2.28M ﹤0.01% 4821
2020
Q1 		$3.33M Buy
124,100
+64,400
+108% +$2.29M ﹤0.01% 3298
2019
Q4 		$1.83M Buy
+59,700
New +$1.65M ﹤0.01% 4556

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's APLS Position: Q1 2026 in Review

Citadel Advisors reduced its Apellis Pharmaceuticals (APLS) stake by 94% in Q1 2026, selling an estimated $13.1M and leaving 38,887 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #6621.

Citadel Advisors first reported a position in APLS in Q2 2018 and has held it in 31 quarters since. The position peaked at $82.2M in Q4 2020. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Citadel Advisors held 38,887 shares of Apellis Pharmaceuticals worth $1.56M as of Q1 2026.
  • Citadel Advisors sold 609,342 Apellis Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6621 holding.
  • Citadel Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
  • Citadel Advisors's Apellis Pharmaceuticals position peaked at $82.2M in Q4 2020.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.